IASLC - What Attendees Can Expect from WCLC25 @iaslc.bsky.social @stephenvliu.bsky.social @narjustflorezmd.bsky.social @drjnaidoo.bsky.social oncodaily.com/blog/wclc25-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC25 #IASLC

Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada @drjnaidoo.bsky.social oncodaily.com/blog/jarushk... #ALKPositive #Cancer #LungHealthCheckIreland #OncoDaily #Oncology

Congrats #DavidOReilly on the PLAN trial: plasma-first liquid biopsy (LB) v tissue (TB) for NSCLC in🇮🇪 @EJCancer - 138pts - 3wk⬇️ time to genomic result,LB>TB - 90% concordance - LB half the cost (micro-cost analysis) @oncoalert.bsky.social @cancertrialsie.bsky.social www.ejcancer.com/article/S095...

🎤 Meet @drjnaidoo.bsky.social , from Beaumont @rcsi.bsky.social  Cancer Centre (Dublin, Ireland) as a speaker at the Targeting RAS Symposium 2025. Dr. Naidoo will give her talk during Session 5 on Day 2 at 09:25h.  🔗 https://targetingras.com/registration/ #TargetingRAS2025 #25anniversaryCIC

What an inspiring video to wake up to! 🙌find strength in your team 🙌defend what is right 🙌you can do ANYTHING but not everything 🙌fight imposter syndrome - you deserve to be there youtu.be/i6fe2EK2lh8?... @solangepeters.bsky.social @drjnaidoo.bsky.social #ESMO #Women4Oncology #oncology

Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM

Although @stephenvliu.bsky.social is hard to follow, we’ve just had an absolute tour de force by @drjnaidoo.bsky.social at #BTOG25 on #SCLC ➡️ Discusses NRG005 and the better outcomes for patients reviving twice daily radiotherapy. ➡️ Continued evidence of a benefit from PCI in LS-SCLC

With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social! @btog.bsky.social #BTOG25

Fantastic over of #radiation induced pneumonitis by #ESTRO President @mguckenberger.bsky.social at #BTOG25 Updates the congress on the new #ESTRO guidelines in this area @drjnaidoo.bsky.social @drpeedell.bsky.social

Long-Term Toxicity of Immune Checkpoint Inhibitors @jama.com Here, our stellar fellow #ChrisCronin charts a roadmap of how to quantitate the nuanced toxicities of IO from irAEs to time toxicity towards IO survivorship #CancerCentreIre @oncoalert.bsky.social #LCSM jamanetwork.com/journals/jam...

Interesting new compound in the KRAS world, BBO-8520 @theaacr.bsky.social - First-In-Class inhibitor of KRAS G12Ci in GTP-Bound (ON)+GDP-Bound (OFF) states - Ph I ONKORAS-101 trial ongoing, BBO-8520+\- pembro @oncoalert.bsky.social @kraskickers.bsky.social #LCSM aacrjournals.org/cancerdiscov...

IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪 Registration & abstract submissions are OPEN! Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC

Delighted to host @medsir.bsky.social today at #BeaumontRCSICancerCentre, exploring novel ways to develop & expand investigator initiated trials for cancer in Ireland 🇮🇪, through @cancertrialsie.bsky.social & beyond Welcome @medsir.bsky.social @rcsi.bsky.social #LCSM

Early detection of lung cancer showcased at #BeaumontHospital GP study day today by #DanielJRyan, ahead of the start of the Beaumont-RCSI-Irish Cancer Society Lung Health Check Pilot Trial, opening this year #EuropeLung #ERS #LungAmbition #RCSI #LCSM

Are you a European clinician🇪🇺 who treats pts with IO & manages #irAEs? Join us in creating a pan-European vision for #irAE care🌍 Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_... @oncoalert.bsky.social

A privilege to be part of the ESMO Women for Oncology Committee! A snapshot of members & the important themes fostered this year: community, leadership, support 🌍 Watch this space for new creative content & events in 2025 🏆 @elinardou.bsky.social @solangepeters.bsky.social

Dying on Xmas day is always so hard on those who are left behind. There is little we can do to make that memory ok. Here, our #PCCM fellow and #IM resident went above & beyond to serenade a dying patient on #Christmas morning. #EOLcare @3wishesprogram.bsky.social

Can patterns of progression on IO, inform future decisions? -1377pts from 5 ph 3 trials used to create 3 PD risk levels - low (⬆️existing lesions), intermediate (new lesions), high (both) - risk score assoc w post-PD OS across tumors Prognostic, so far #LCSM jamanetwork.com/journals/jam...

#ESMOImmuno24 Proffered paper🔥 Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social - no PFS/OS benefit - g3+TRAE 57%, 54%, 49% - concerning pneumonitis signal Concurrent RT+IO - going going gone @oncoalert.bsky.social #LCSM #Medsky #Oncsky

#ESMOImmuno24 Proffered paper🔥 Gut microbiome in Ph III NIPPON trial (N/I/chemo v Pembro/chemo 1L) #JCOG - Fusicatenibacter, Butyricicoccus = ⬆️ OS (esp with N+I: HR 0.56, 0.52) & ⬇️severe irAEs - Blautia = ⬆️OS - Prevotella species = ⬇️OS with N+I @oncoalert.bsky.social #MedSky #OncSky #LCSM

Ph 1/2 trial selinexor+docetaxel in adv KRAS+ NSCLC @theaacr.bsky.social - selinexor is a XPO1 inhibitor with activity in KRAS+ PDX models, p53 is neg predictor of response - 40pts, MTD 60mg weekly - ORR 80 v 27% KRAS+/p53WT v p53+ @oncoalert.bsky.social #LCSM aacrjournals.org/clincancerre...

Can gender & genetics impact alectinib tox? @jtoonline.bsky.social - 215pts with ALK+ NSCLC - women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001 - Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox #Medsky #Oncsky #LCSM www.jto.org/article/S155...

Tables and Tornadoes: The Best Tools for the Job? Tables (sometimes BIG) are among most routinely used tools to show data like baseline characteristics & AEs, while “tornado plots” are a standard figure to display AEs & sometimes other variables. But could we do better, esp for live talks? (1/8)

FDA approves durvalumab for LS small cell lung cancer based on Ph III ADRIATIC trial: - PFS benefit (HR 0.76) - OS benefit (HR 0.73) - 2 yrs durvalumab after definitive chemoRT - currently available in 🇮🇪 on EAP www.fda.gov/drugs/resour... #MedSky #OncSky #LcSM @oncoalert.bsky.social

Great summary in @Annals_Oncology of an intensive few days in March 2024 discuss the key issues confronting lung cancer care globally, thanks to Dr. @mayluciemeyer for her excellent leadership on this manuscript! #lcsm @IASLC @myESMO www.sciencedirect.com/science/arti...

Now is the winter of our discontent Richard III 1.1 #ShakespeareSunday #WinterTheme #GameofThrones

Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist - 3211pts, ConcertAI database - 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4% - s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE @oncoalert.bsky.social #MedSky #OncSky #LCSM academic.oup.com/oncolo/advan...

Phase II study of durvalumab + tremelimumab + chemotherapy in #EGFR NSCLC post TKI @jtoonline.bsky.social (n=100). In T790M- (including 1L osi), RR 31% (none in PDL1 negative), DOR 9.5m, PFS 6.5m. In T790M+ (with 2L osi), RR 21%, DOR 6.3m, PFS 4.9m. Modest activity. www.jtocrr.org/article/S266...

Impact of cycle 1 irAEs on ICI outcomes: - 683pts from SWOG DART trial - g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001 - g3+ irAEs = ⬇️OS HR  1.41 p= .025 - g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002 Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social academic.oup.com/jnci/advance...

Ph I trial ABBV-011 (SEZ6-ADC) in SCLC @theaacr.bsky.social - SEZ6: Seizure-Related Homolog Protein 6 (IHC+ in SCLC) - 99pts, 67% 2+lines - TRAEs fatigue 50% nausea 42% - 1mg/kg dose ORR 25% - mDOR 4.2m One to watch in SCLC @oncoalert.bsky.social #OncSky #LCSM aacrjournals.org/clincancerre...

Interesting paper identifies 3 subgrps of pulm carcinoid @jtoonline.bsky.social - 3 subtypes by mRNA & 🇳🇱registry by IHC - A1=OTP+/ASCL1+/HNF1A (53%) - A2=OTP+/ASCL1/HNF1A+ (38%) - B=OTP/ASCL1/HNF1A+ (9%) Nxt step- assist tx selectn? www.jto.org/article/S155... #Oncsky #LCSM @oncoalert.bsky.social

The science version of “what doesn’t kill me makes me stronger”: Scientists with ‘near misses’ early in their careers outperform those with ‘narrow wins’ in the longer run. www.nature.com/articles/s41...

OncoAlert and partners (ESSO, ESGO, MASCC & SIOG) Proudly Announce 2/3 of our faculty, more soon Register HERE buff.ly/3CChgre @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @erikahamilton9.bsky.social @agerikssonmd.bsky.social @drjnaidoo.bsky.social

Women are under-represented at senior levels in #academia globally, & across all #science 🧪 disciplines, as shown by these "scissor-shaped curves" ✂️ So how can we ever achieve #gender #equality? We discuss various strategies in this #Cell Commentary #WomeninSTEM www.cell.com/cell/fulltex... 🧵 1/

Why strew'st thou sugar on that bottled spider, Whose deadly web ensnareth thee about? Richard III 1.3 #ShakespeareSunday #GameofThrones

#Gathering24 @mskcancercenter.bsky.social reunion! Welcome @adamjschoenfeld.bsky.social & #AlexShoushtari. Great talks on advances in cell therapy for NSCLC & melanoma, at the Gathering around Cancer in Dublin ☘️ @mskcancercenter.bsky.social #RoisinOCearbhail #MeganGreally #JohnMcCaffrey

#Gathering24 Superb 🇮🇪young investigator session at the Gathering in Cancer meeting, in Dublin today: - ctDNA in NSCLC @davidoreilly.bsky.social #beaumontrcsi - melanoma #SarahLochrin #mskcc - GI cancer #TimOBrien - oncogene+ NSCLC @drdavidmcmahon.bsky.social - HCC #harryharvey Well done all🏆

This is a nice review on chromothripsis (aka chromosomal shattering) when a single catastrophic event is associated with lots of genomic rearrangements www.nature.com/articles/s41...

Phase III EXTENTORCH study now in JAMA Oncology - first line chemotherapy +/- toripalimab for advanced #SCLC (n=442). Adding toripalimab improved PFS (HR 0.67) and OS (14.6m from 13.3m, HR 0.80). Of note, >20% of pts had no smoking history - a consistent trend. #LCSM jamanetwork.com/journals/jam...

go.bsky.app/P1zYwRs Please share with others in the Radiation Oncology/Cancer Research space in Ireland.

@iaslc.bsky.social & LCRF announced the recipient of their first-ever IASLC - LCRF Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers. The $2.5M, 4-year grant was awarded to a team led by David A. Barbie, MD, of @danafarber.bsky.social. LCRF.org/teamscience2024

Sharing a fledgling #LCSM starter pack for those joining Bluesky 🦋 #Medsky #Oncsky @oncoalert.bsky.social go.bsky.app/MjDxbG2

'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social: - 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking - Retrieval identified 90% suitable trials - 42% time-saving in matching a patient to a trial Like, wow #MedSky #OncSky #LCSM www.nature.com/articles/s41...

Inspired by the other amazing starter packs - here's one for cancer researchers! I tried to make this broad - from immunology to genomics to cell biology and so much more.. This list also includes organizations & institutes supporting cancer researchers 🧪🔬⚕️🩺 Hope its useful! go.bsky.app/FEoaJMc

Action is eloquence Coriolanus 3.2 #ShakespeareSunday #MedSky #Oncsky

Superb opinion piece on PCI in SCLC: do we need it in the IO era? Key points: - PCI optional in ES SCLC IO trials - MRI surveillance acceptable in non IO era - in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms #LCSM #MedSky #OncSky www.sciencedirect.com/science/arti...

Paper by Piro Lito et al shows new tricomplex RAS inhibitors "inactivate mutant RAS in a bimodal manner: by preventing effectors from being recruited to active state of RAS and/or by enhancing the ability of RAS mutants to hydrolyze GTP leading to their inactivation." www.nature.com/articles/s41...

Great to see our young ones at the ESMO Lung Preceptorship 🫁 🇫🇷 Thanks #ESMO for your commitment to training the next generation 🇮🇪 #LCSM

Good morning blue sky 🦋 Hoping to see #LCSMers here Debate, discussion, friendship, community, progress 🏆 @n8pennell.bsky.social @stephenvliu.bsky.social @pateloncology.bsky.social @tnewsomdavis.bsky.social @drtomjohn.bsky.social @jillfeldman4.bsky.social @jackwestmd.bsky.social #LCSM